ARTICLE | Deals
Flagship revisits company combination strategy with Sonata
The Cygnal-Inzen mashup is taking a microenvironment-focused approach to cancer, fibrosis and autoimmunity.
May 19, 2022 2:55 AM UTC
Flagship Pioneering’s Sonata, a mash-up of portfolio companies Inzen and Cygnal, is focusing on the cellular microenvironment as an inroad into cancer, fibrosis and autoimmune disorders.
Sonata Therapeutics is the fourth composite company Flagship has disclosed in the past six years. ...